Trials / Completed
CompletedNCT05117177
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
A Multicenter, Open-Label, Phase I Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Food-Effect of Inupadenant New Formulations in Participants with Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- iTeos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A2A-004 is a three-part multicenter, open-label, Phase I clinical trial intended to evaluate the safety and tolerability, and the pharmacokinetics (PK) and food effect of new formulations of inupadenant (formerly known as EOS100850), in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inupadenant | Oral administration |
| DRUG | Inupadenant | Oral administration |
| DRUG | Inupadenant | Oral administration |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2024-05-09
- Completion
- 2024-05-09
- First posted
- 2021-11-11
- Last updated
- 2024-09-19
Locations
5 sites across 2 countries: Belgium, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05117177. Inclusion in this directory is not an endorsement.